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Abstract: Phosphodiesterase 5 (PDE5) is one of the most extensively studied phosphodiesterases 
that is highly specific for cyclic-GMP hydrolysis. PDE5 became a target for drug development based 
on its efficacy for treatment of erectile dysfunction. In the present study, we synthesized four novel 
analogues of the phosphodiesterase type 5 (PDE5) inhibitor—tadalafil, which differs in (i) ligand 
flexibility (rigid structure of tadalafil vs. conformational flexibility of newly synthesized 
compounds), (ii) stereochemistry associated with applied amino acid building blocks, and (iii) 
substitution with bromine atom in the piperonyl moiety. For both the intermediate and final 
compounds as well as for the parent molecule, we have established the crystal structures and 
performed a detailed analysis of their structural features. The initial screening of the cytotoxic effect 
on 16 different human cancer and non-cancer derived cell lines revealed that in most cases, the 
parent compound exhibited a stronger cytotoxic effect than new derivatives, except for two cell 
lines: HEK 293T (derived from a normal embryonic kidney, that expresses a mutant version of SV40 
large T antigen) and MCF7 (breast adenocarcinoma). Two independent studies on the inhibition of 
PDE5 activity, based on both pure enzyme assay and modulation of the release of nitric oxide from 
platelets under the influence of tadalafil and its analogues revealed that, unlike a reference 
compound that showed strong PDE5 inhibitory activity, the newly obtained compounds did not 
have a noticeable effect on PDE5 activity in the range of concentrations tested. Finally, we 
performed an investigation of the toxicological effect of synthesized compounds on Caenorhabditis 
elegans in the highest applied concentration of 6a,b and 7a,b (160 μM) and did not find any effect 
that would suggest disturbance to the life cycle of Caenorhabditis elegans. The lack of toxicity 
observed in Caenorhabditis elegans and enhanced, strengthened selectivity and activity toward the 
MCF7 cell line made 7a,b good leading structures for further structure activity optimization and 
makes 7a,b a reasonable starting point for the search of new, selective cytotoxic agents. 
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1. Introduction 
Phosphodiesterase type 5 (PDE5) also called the cGMP-specific, cGMP-binding PDE, 
is the major cGMP-hydrolyzing PDE in platelets, lung, and the vascular smooth muscle 
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of the penile corpus cavernosum. This ubiquitous enzyme decreases 3′,5′-cyclic guanosine 
monophosphate (cGMP) or 3′,5′-cyclic adenosine monophosphate (cAMP) in target cells 
by catalyzing the hydrolysis of these second messengers. PDE 5 inhibitors stop the 
enzyme in blood vessel walls from working properly and cause blood vessels muscle to 
relax. Tadalafil (1) (Figure 1) is a highly potent and highly selective phosphodiesterase 
type 5 (PDE5) inhibitor [1,2] which has gained wide recognition as an efficient agent for 
treatment of erectile dysfunction [3–5] with limited adverse effects [6] and a prolonged 
mode of action [7,8]. As a long-lasting PDE5 inhibitor, it was also approved in 2009 by the 
US Food and Drug Administration (FDA) for the treatment of pulmonary arterial 
hypertension (PAH) [9–12] and for the treatment of lower urinary tracts symptoms (LUTS) 
associated with benign prostatic hyperplasia (BPH) [13,14]. Koka et al. reported that 
tadalafil could be used as a protective agent in cancer treatment and could attenuate 
doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect 
[15]. Tadalafil, exhibiting a weak cytotoxic effect, significantly enhanced the colchicine 
and paclitaxel sensitivity in MDR ABCB1-overexpressing KB-C2 cells and the vincristine 
and paclitaxel in HEK/ABCB1 cells [16]. Booth reported that in multiple tumor cell types, 
including anoikis resistant and stem cell-like cells, sildenafil (and tadalafil) interacted with 
celecoxib to promote killing in short-term assays and long-term colony formation assays 
[17]. Initially, it was assumed that tadalafil (and other PDE 5 inhibitors) could influence 
antiproliferation and proapoptotic mechanism in various carcinomas with special 
importance particularly in carcinoma cells with enhanced PDE5 expression [18]. A recent 
review [19] indicated the importance and the potential of tadalafil as an anticancer agent, 
which exhibited cytotoxic effects and the reduction of tumor growth in collateral [20,21], 
HNSCC [22] and thyroid [23] cancers, as well as improved survival in a murine model of 
brain lymphoma with rituximab treatment [24]. Finally, Kassel reported that tadalafil can 
improve clinical outcome of advanced melanoma patients by enhancing anti-tumor 
immunity and suggested its potential application in combined melanoma 
immunotherapy [25]. 
 
Figure 1. Tadalafil (1), its equipotent phosphodiesterase 5 (PDE5) inhibition analogues 2, 
analogues with cytotoxic 3, antiplasmodial 4, procognitive 5 activities and newly synthesized 
compounds 6a,b and 7a,b. 
Consequently, in recent years many different analogues of tadalafil were synthesized 
[26,27] (Figure 1). Using computer-aided molecular modeling, 2 analogues were designed 
and synthesized, which exhibited equipotent PDE inhibition activity [28–30]. Abadi at al. 
reported [31] that bromine-modified series of tadalafil, such as compound 3, demonstrate 
both strong PDE inhibition activity (IC50 = 0.06 μM for 3) and a moderate cytotoxic effect 
against the colon cancer cell line HT29 (IC50 = 25.5 μM for 3). The stereochemical effect on 
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cytotoxic behavior was also determined, and surprisingly the presence of a chiral center 
derived from amino acid with the S configuration (L-tryptophan) resulted in more 
cytotoxic isomers than those derived from amino acid with the R configuration (D-
tryptophan), even if such derivatives exhibited lower PDE inhibition activity. The 
structure of tadalafil was a starting point for the development of antiplasmodial agents, 
utilizing the structural differences between human and plasmodial PDE5 orthologues 
[32]. It was revealed that compound 4 kills the parasite via the inhibition of plasmodial 
PDE activity (pIC50 = 6.3 μM). These results prove that the cAMP/cGMP pathways could 
be desirable therapeutic targets against Plasmodium falciparum and antiplasmodial 
derivatives could act as inhibitors of the hydrolysis of cyclic nucleotides of the parasite. 
In 2018, Mao et al. and Ni et al. reported [33,34] the first example of dual-target inhibitors 
for AChE and PDE5 as potentially novel therapeutic agents for the treatment of 
Alzheimer’s disease (AD). The lead compound 5 has been confirmed to demonstrate 
memory-enhancing effects in AD mouse models, exhibiting AChE and PDE5A1 inhibition 
at IC50 = 0.032 μM and IC50 = 1.53 μM, respectively. 
As the diketopiperazine framework is a well-recognized privileged structure, and a 
diketopiperazine ring is present in many bioactive compounds and drugs [35–37], we 
decided to design, synthesize and investigate the biological activity of some flexible 
tadalafil analogues based on the diketopiperazine scaffold on different biological models 
and compare their physicochemical and biological properties and features with the parent 
compound. In our study, we decided to investigate the influence and importance of 
inhibitor flexibility, stereochemical effect and substitution with bromine atom on 
biological activity and binding to PDE5. These studies are a continuation of our previous 
research on the development of new synthetic routes, and the search for biological activity 
of dilactam derivatives containing six-membered dilactam rings in their structure 
(hexahydro-2H-pyrazino[1,2-a]pyrazine-6,9-dione derivatives) [38], seven-membered 
dilactam rings (1,2,3,4,12,12a-hexahydrobenzo[e]pyrazino[1,2-a][1,3]diazepine-6,11-
dione derivatives) [39–42] and eight-membered dilactam rings 
(dibenzo[b,f][1,5]diazocine-6,12(5H,11H)-dione and 5,12-
dihydrodibenzo[b,f][1,4]diazocine-6,11-dione derivatives) [43–46]. 
2. Results 
2.1. Chemistry 
The designed synthetic path begins from a dipeptide formation reaction, where 
protected D- 8a or L-tryptophane 8b reacts with sarcosine benzyl ester tolenesulfonate (9) 
in the presence of PyBroP and DIPEA (Scheme I). The reaction, monitored by TLC and 
LRMS(ESI) spectra, was completed after 18 h. Purification of intermediates 10a,b 
produced unsatisfactory results, thus the obtained dipeptides 10a,b were directly treated 
with 25% piperidine in dichloromethane, which resulted in the removal of the Fmoc 
group. The concomitant cyclisation to the diketopiperazine led to the products 11a,b 
easily isolated and purified by column chromatography. Obtained diketopiperazine 
intermediates 11a,b were then treated with 5-(bromomethyl)benzo[d][1,3]dioxole or 5-
bromo-6-(bromomethyl)benzo[d][1,3]dioxole, in the presence of cesium carbonate, which 
led to the formation of the appropriate N-benzylated derivatives 12a,b and 13a,b. An 
initial attempt to use potassium carbonate instead of cesium carbonate did not yield the 
requested products. The final step, the removal of the Boc group, was performed by 
treating Boc derivatives 12a,b and 13a,b with 25% TFA in DCM. The obtained products 
6a,b and 7a,b were isolated and purified by column chromatography and further used in 
biophysical and biochemical studies. 




Scheme I. The synthesis of compounds 6a,b and 7a,b. 
2.2. Crystallographic Studies 
Attempts to obtain single-crystals suitable for diffractometric measurements of all 
synthesized compounds were undertaken, however, the goal was achieved only in four 
cases. Compounds 11a, 12a and 1 were obtained by slow evaporation from butanol-2 
solution, while 6a was obtained from slow evaporation from methanol. 
The identity of the investigated compounds was confirmed by single-crystal X-Ray 
diffraction analysis (Figures 2–10). It turned out that they were crystallizing in the 
monoclinic P21 (11a and 1) or orthorhombic P212121 (12a and 6a) space groups with one (1, 
6a, 12a) or two (11a) molecules of compound in the asymmetric unit of the crystal lattice 
(Figures 2a, 4, 6 and 8). The details of crystallographic data and the refinement parameters 
are summarized in Table S1. The full list of values of bond lengths, valence and torsion 
angles can be found in the Supporting Information (Tables S2–S13). 
The alignment of structural skeletons of both molecules comprising the asymmetric 
unit of 11a (Figure 2b) reveals that their geometry is different. The main difference is 
related with the spatial orientation of the 3,6-dioxopiperazinyl moieties relative to the 
indole ring system. The mean-quadratic planes delineated by non-hydrogen atoms of 
mentioned fragments are inclined to themselves by the angle of 35.7(2)° and 44.1(2)° in 
case of molecules A and B, respectively. A close look at Figure 2b reveals also that t-butyl 
fragments in A and B are slightly twisted relative to each other. In both aforementioned 
molecules, the carbonyl group of the t-butylcarboxylate moiety is coplanar with the indole 
ring system. Specific molecular geometry is causing the appearance of several weak 
intramolecular C−H···O, C−H···π and C=O···π contacts (Tables S14–S16). 
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Figure 2. Asymmetric unit of the crystal lattice with crystallographic numbering (a) and 
superimposed molecules of 11a (b). Displacement ellipsoids are drawn at the 50% probability level 
and the H-atoms were omitted for clarity. The intramolecular C=O···π contact is represented by the 
dotted line. Cg1, Cg3 and Cg5 denote the geometric centres of gravity of the aromatic rings 
delineated by the N1A/C1A−C3A/C8A, C3A−C8A and N1B/C1B−C3B/C8B atoms, respectively. 
In the crystal, adjacent molecules of 11a are involved in a dense network of N−H···O 
(d(D···A) = 2.908(6)–2.919(6) Å; <(D−H···A) = 154(7)–157(6)°, Table S14) and C−H···O 
(d(D···A) = 2.901(6)–3.459(7) Å; <(D−H···A) = 114–163°, Table S14) hydrogen bonds that are 
leading to the rise of infinite layers spreading along the (001) plane (Figure 3a). Molecules 
in these layers are arranged in a characteristic ‘herring-bone’ manner (Figure 2b). The 
whole crystal network is stabilized by the weak C−H···π contacts (d(D···A) = 3.490(6)–
3.540(6) Å; <(D−H···A) = 122–126°, Table S15) involving neighboring molecules in adjacent 
layers (Figure 3b). 
 
Figure 3. Arrangement of molecules of 11a in the crystal, where: (a) layer of molecules spreading 
along (001) plane; (b) general view on layered supramolecular architecture of compound viewed 
along c-direction (single layers are highlighted in light-green). The H-atoms not involved in 
intermolecular interactions have been omitted for clarity. The N−H···O and C−H···O hydrogen 
bonds are represented by dashed lines, while the C−H···π contacts by dotted lines. Symmetry 
codes: (i) x + 1, y, z; (ii) x − 1, y, z; (iii) x, y, z + 1; (iv) −x + 1, y + 1/2, −z; (v) −x + 1, y − 1/2, −z + 1. 
In case of 12a, the mean-quadratic planes of indole and 3,6-dioxopiperazinyl in the 
molecule are inclined to each other by a 33.72(19)° angle, while the 3,6-piperazinyl and 5-
methylbenzo[d][1,3]dioxazole fragments are oriented nearly perpendicular to themselves. 
The angle between mean planes defined by the non-hydrogen atoms of above moieties is 
80.97(17)°. As in the case of 11a, here also intramolecular C−H···O and C−H···π contacts 
were found (Tables S17 and S18). 




Figure 4. Asymmetric unit of the crystal lattice of 12a with crystallographic numbering. 
Displacement ellipsoids are drawn at the 50% probability level and the H-atoms were omitted for 
clarity. Cg2 and Cg5 denote the geometric centres of gravity of the aromatic rings delineated by the 
N1/C1−C3/C8 and C20−C25 atoms, respectively. 
Adjacent molecules of 12a in the crystal are held together via the network of 
bifurcated C−H···O hydrogen bonds (d(D···A) = 3.418(7)–3.452(7) Å; <(D−H···A) = 146–163°, 
Table S17) into infinite chains running along the [001] direction (Figure 5a). The molecules 
from neighboring chains are further interacting by themselves by the network of weak 
C−H···O hydrogen bonds (d(D···A) = 2.987(8) Å; <(D−H···A) = 117°, Table S17) and C−H···π 
contacts (d(D···A) = 3.362(9) Å; <(D−H···A) = 135°, Table S18), which is leading to the rise 
of infinite layers spreading along the (100) plane (Figure 5b). Whole layered 
supramolecular architecture is stabilized by the presence of weak C−H···π contacts 
(d(D···A) = 3.896(7) Å; <(D−H···A) = 170°, Table S18) between adjacent molecules in 
neighboring layers (Figure 5c). 
 
Figure 5. Arrangement of molecules of 12a in the crystal, where: (a) chain of molecules running 
along [001] direction; (b) single layer of molecules spreading along (100) plane (single chain of 
molecules is highlighted in blue); (c) general view on layered supramolecular architecture of 
compound viewed along a-direction (single-layers are highlighted in light-green). The H-atoms 
not involved in intermolecular interactions have been omitted for clarity. The C−H···O hydrogen 
bonds are represented by dashed lines, while the C−H···π contacts by dotted lines. Symmetry 
codes: (i) x − 1, y, z; (ii) –x + 3/2, –y + 1, z − 1/2; (iii) −x + 1, y + 1/2, −z + 3/2; (iv) −x + 1/2, −y + 1, −z + 
3/2. 
The mean-quadratic planes of indole and benzo[d][1,3]dioxazole moieties in case of 
the molecule of 6a are inclined by the angles of 36.15(9) and 93.08(8)° relative to the 3,6-
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dioxopiperazinyl moiety. A detailed analysis of molecular interactions allowed us to 
identify the existence of one weak intramolecular C−H···π contact (Table S20). 
 
Figure 6. Asymmetric unit of the crystal lattice of 6a with crystallographic numbering. 
Displacement ellipsoids are drawn at the 50% probability level and the H-atoms were omitted for 
clarity. Cg2 and Cg4 denote the geometric centres of gravity of the aromatic rings delineated by the 
N1/C1−C3/C8 and C3−C8 atoms, respectively. 
In the crystal of 6a, neighboring molecules of the investigated compound are 
incorporated in the N−H···O hydrogen bonds (d(D···A) = 2.895(3) Å; <(D−H···A) = 171(3)°, 
Table S19), which is leading to the appearance of an infinite chain running along [001] 
direction (Figure 7a). Adjacent molecules in neighboring supramolecular assemblies of 
this type are then interacting by themselves via the weak C−H···O hydrogen bonds 
(d(D···A) = 3.254(4) Å; <(D−H···A) = 170°, Table S19). This results in the formation of infinite 
layers spreading along (100) plane (Figure 7b). Whole, layered supramolecular 
architecture of 6a is stabilized by the presence of weak C−H···π contacts (d(D···A) = 3.451(4) 
Å; <(D−H···A) = 127°, Table S20) and bifurcated C−H···O hydrogen bonds (d(D···A) = 
3.345(4)–3.385(4) Å; <(D−H···A) = 155−171°, Table S19) involving adjacent molecules in 
neighboring layers (Figure 7c). 
 
Figure 7. Arrangement of molecules of 6a in the crystal, where: (a) chain of molecules running 
along [001] direction; (b) single layer of molecules spreading along (100) plane (single chain of 
molecules is highlighted in blue); (c) general view on layered supramolecular architecture of 
compound viewed along a-direction (single layers are highlighted in light green). The H-atoms not 
involved in intermolecular interactions have been omitted for clarity. The N−H···O and C−H···O 
hydrogen bonds are represented by dashed lines, while the C−H···π contacts by dotted lines. 
Symmetry codes: (i) –x + 1/2, –y + 1, z − 1/2; (ii) –x + 1, y − 1/2, –z + 1/2; (iii) –x + 3/2, –y + 1, z +1/2 ; 
(iv) –x, y + 1/2, –z + 1/2. 
Molecule 1 (tadalafil) consists of the lactam and indole moieties (Figure 8). The unit 
cell parameters and geometric features describing the molecular skeleton of the 
compound presented in this work are in good agreement with the structure of tadalafil 
previously reported by Daugan et al. [2]. Although in our research diffractometric 
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measurements of the investigated system were conducted at 100(2) K instead of room 
temperature, no phase transition was observed. 
 
Figure 8. Asymmetric unit of the crystal lattice 1 with crystallographic numbering. Displacement 
ellipsoids are drawn at the 50% probability level and the H-atoms were omitted for clarity. Cg2 
and Cg6 denote the geometric centres of gravity of the aromatic rings delineated by the 
N3/C13/C8−C7/C14 and C15−C20 atoms, respectively. 
The alignment of tadalafil molecule with the molecules of three compounds, of which 
the crystal structures are described above (6a, 11a and 12a), highlights the existence of 
significant structural differences between them. A close look at Figure 9 reveals clearly 
that diketopiperazine moiety in 6a, 11a and 12a is much more bent above or below the 
plane of the indole unit compared to that what is observed within the rigid 
pyrazinopyridoindole core in 1. It can be seen also that all derivatives with disjointed 
diketopiperazine and indole moieties indicate noticeable conformational flexibility. 
 
Figure 9. Superimposed molecules of 1, 6a, 11a and 12a. The H-atoms were omitted for clarity. 
In the crystal, adjacent molecules of 1 are held together by the network of N−H···O 
(d(D···A) = 2.968(3) Å; <(D−H···A) = 171(4)°, Table S21) and C−H···O (d(D···A) = 3.373(4) Å; 
<(D−H···A) = 154°, Table S21) hydrogen bonds into infinite chains running along [010] 
direction (Figure 10a). The above-mentioned supramolecular assembly is stabilized by the 
presence of weak intermolecular C−H···π contacts (d(D···A) = 3.550(3)–3.690(3) Å; 
<(D−H···A) = 139–167°, Table S22). Neighboring chains further interact by weak C−H···O 
hydrogen bonds (d(D···A) = 3.176(4) Å; <(D−H···A) = 151°, Table S21), which results in an 
arising of an infinite layer of molecules spreading along the (001) plane (Figure 10b). 
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Finally, layered supramolecular architecture of 1 is stabilized via the network of weak 
C−H···O hydrogen bonds (d(D···A) = 3.476(5) Å; <(D−H···A) = 171(4)°, Table S21) engaging 
adjacent molecules of compounds in neighboring layers (Figure 10c). 
 
Figure 10. Arrangement of molecules of 1 in the crystal, where: (a) chain of molecules running 
along [010] direction; (b) single layer of molecules spreading along (001) plane (single chain of 
molecules is highlighted in blue); (c) general view on layered supramolecular architecture of 
compound viewed along a-direction (single layers are highlighted in light green). The H-atoms not 
involved in intermolecular interactions have been omitted for clarity. The N−H···O and C−H···O 
hydrogen bonds are represented by dashed lines, while the C−H···π contacts by dotted lines. 
Symmetry codes: (i) –x + 1/2, –y + 1, z − 1/2; (ii) –x + 1, y − 1/2, –z + 1/2; (iii) –x + 3/2, –y + 1, z +1/2 ; 
(iv) –x, y + 1/2, –z + 1/2. 
2.3. Cytotoxic Effect 
The synthesized compounds 6a,b and 7a,b, together with tadalafil, were tested in 
vitro to determine their cytotoxic activity against sixteen cancer cell lines: epidermoid 
carcinoma A-431, lung carcinoma A549, colorectal carcinoma HCT116 and HCT116p53−/−, 
glioblastoma U-87 MG and U-251, breast adenocarcinoma MCF7 and MDA-MB-231, 
cervical squamous cell carcinoma SKG-IIIa, cervical adenocarcinoma HeLa, bone 
osteosarcoma U-2 OS, hepatocellular carcinoma HEPG2, larynx squamous cell carcinoma 
BICR 18 and non-cancer cell lines: kidney HEK 293T (expresses a mutant version of SV40 
large T antigen) and normal fibroblasts MRC-5 and BJ. Additionally, the anticancer drug, 
cisplatin, was used as a positive control. The viability results and obtained half maximal 
inhibitory concentrations (IC50) are shown in Figure 11 and Table 1. The cytotoxicity of 
each derivative of the tadalafil was different depending on the dose and type of treated 
cell line. The highest toxicity was observed for all analogues in HEK 293T and MCF7 cell 
lines. Only these lines were more sensitive to 6a,b and 7a,b than to tadalafil (Figure 11g 
and n, and Table 1, bold digits). For most cell lines, compounds 7a,b were slightly more 
toxic in comparison to 6a,b. The least cytotoxic effect was observed for U-251 MG cells, 
where the IC50 values for all studied analogues were above 160 μM (Figure 11f and Table 
1). Overall, the results clearly demonstrate that only analogues 7a and 7b, where IC50 
values were only about three times higher in comparison to cisplatin (Table 1) and in the 
highest two concentrations dropped to a similar percentage of survival as for this drug 
(Figure 11g); they could be considered as candidates for selective anticancer treatment. 
Since the mechanism of action of the tested compounds is not determined and the ob-
tained cytotoxic effect is low, it is difficult to precisely explain the greater cytotoxic effect 
of the bromine substituted compounds 7a and 7b than their analogues 6a and 6b. It is 
known, however, that the presence of bromine in the ligand can cause the formation of 
additional halogen bonds at the active site of the protein and thus increase the binding of 
the ligand to the protein. Bromine substituted compounds may also be better suited to the 
hydrophobic pocket in the active side of the protein. 














Figure 11. Viability of selected human cell lines in response to tadalafil and its analogues 6a,b, 
7a,b, and cisplatin evaluated with MTT metabolism assay. A-431 (a), A549 (b), HCT116 (c), 
HCT116p53−/− (d), U-87 MG (e), U-251 MG (f), MCF7 (g), MDA-MB-231 (h), SKG-IIIa (i), HeLa (j), 
U-2 OS (k), HEPG2 (l), BICR 18 (m), HEK 293T (n), MRC-5 (o) and BJ (p). Cells were incubated 
with increasing concentrations (range = 1.25–160 μM) of tadalafil, compounds 6a,b, 7a,b, and 
cisplatin for 72 h. Percentage of cell viability inhibition was calculated in comparison to cells 
treated with DMSO only (regarded as a control). Each point of curves represents the mean ± SD of 
at least three independent experiments done in triplicate. Nonlinear fit of the dose-log response 
curves was done in GraphPad Prism 5.03. 
Table 1. Calculated IC50 values of tadalafil and its analogues 6a,b, 7a,b, and cisplatin on selected human cell lines. 
Comp. No. 6a 6b 7a 7b Tadalafil Cisplatin 





















































































































































































IC50—half maximal inhibitory concentration (lethal dose for 50% of cells). IC50 values were calculated from the nonlinear fit of 
the dose-log response curves done in GraphPad Prism 5.03. Values are medians of at least three independent experiments. 
* 95% Confidence Intervals, ** % of proliferation inhibition at highest concentration used—160 μM. 
2.4. Enzyme Inhibition 
Additionally, for all four compounds and tadalafil, as the control, the inhibitory 
activities against PDE5 were determined with the aid of a colorimetric PDE Activity Assay 
Kit (Abcam). A high concentration of cGMP substrate was used (200 μM) due to the 
moderate sensitivity of the aforementioned assay. This concentration of cGMP was 
approximately 100 times above the apparent Km, so the direct comparison with earlier 
reported tadalafil IC50 values was impossible. To obtain direct binding affinity 
(independent of substrate concentration), we converted measured IC50 value into 
inhibition constant (Ki) using the Cheng–Prusoff equation [47], assuming Km = 2.0 ± 0.5 
μM [48]. The results are shown in Figure S41 and Table 2. 
Table 2. Calculated IC50 and Ki values of tadalafil and its analogues 6a,b, 7a,b against human 
PDE5. 
Compound No. IC50 (μM) Ki (μM) 
6a 137 ± 47 1.4 ± 0.8 
6b 260 ± 210 2.6 ± 2.7 
7a 22 ± 12 0.22 ± 0.17 
7b 39 ± 27 0.39 ± 0.36 
tadalafil 0.072 ± 0.031 (7.1 ± 4.8) × 10−4 
IC50—half maximal inhibitory concentration. IC50 values were calculated by global fitting of the 
sigmoidal dose-response equation done in Origin 9.0. 
Calculated binding affinity for tadalafil is similar to earlier reported IC50 values for 
PDE5 that vary from ~1–2 nM [49,50]. Unfortunately, none of these newly synthesized 
analogs exhibit significant inhibitory activity against human PDE5, since the most potent 
of them—7a is over 300 less effective than tadalafil. However, we can observe an increase 
in the PDE5 inhibitory activity for brominated analogs 7a,b compared to unsubstituted 
(6a,6b). Moreover, the unsubstituted (S) isomer 6a is a significantly less effective inhibitor 
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than the (R) isomer 6a and the same tendency is observed for their halogenated 
counterparts. 
2.5. Antiplatelet Activity of the Tested Compounds 
Nitric oxide is one of the main physiological antiplatelet molecules secreted by 
vascular endothelium. It stimulates intraplatelet production of cGMP. This secondary 
messenger is then decomposed in platelets by the activity of two out of three PDE isoforms 
which are detected in platelets, namely by PDE2 and PDE5, while the other isoform 
(PDE3) is mostly involved in cAMP hydrolysis [51]. Inhibitors of these 
phosphodiesterases increase intraplatelet concentration of cGMP and thus potentiate the 
antiplatelet effect of NO [52]. Sildenafil has been shown to possess such a potentiating 
effect in a model of blood platelet aggregation [53]. Present studies were aimed to verify 
antiplatelet activity of four newly synthesized PDE5 inhibitors with the use of tadalafil as 
a reference. Antiplatelet activity of the compounds was tested by means of light 
transmittance aggregometry in platelet-rich plasma stimulated with collagen in presence 
of a donor of nitric oxide (DEA-NO). As shown in Figure 12, tadalafil in presence of DEA-
NO inhibited platelet aggregation by approx. 50%, while none of the tested analogues 
presented significant antiplatelet activity. 
 
Figure 12. Inhibition of blood platelet aggregation (BPA) by tadalafil and its analogues in the 
presence of DEA-NO evaluated by light transmittance aggregometry. Platelet rich plasma was 
preincubated for 5 min with tadalafil (10 μM) or its analogues, 6a,b, 7a,b (10 μM). Shortly prior to 
measurement, 500 nM DEA-NO was added, followed by 2 μg/mL collagen. Percentage of 
inhibition of platelet response was calculated in comparison to a sample treated with DMSO and 
DEA-NO on the basis of maximal value of platelet aggregation. Black horizontal lines on data 
points show means and standard deviations. Statistical analysis was performed via one-way 
analysis of variance with Tukey’s multiple-comparison test (***, p < 0.001). 
2.6. Toxicity Against Caenorhabditis Elegans 
We also performed an investigation on the toxicological effect of synthesized 
compounds on Caenorhabditis elegans. In the highest applied concentration—160 μM, 6a,b 
and 7a,b did not exhibit any toxicity in C. elegans after 48 h exposure. 
3. Materials and Methods 
3.1. Chemistry 
3.1.1. General 
Commercially available chemicals were of reagent grade and used as received. 
Purification of the compounds was performed by column chromatography on silica gel 
60 M (0.040–0.063 mm, E. Merck, Darmstadt, Germany). Thin layer chromatography 
(TLC), using silica gel plates (Kieselgel 60F254, E.Merck), was used to monitor reaction 
progress. A B-540 Melting Point apparatus (Büchi, New Castle, DE, USA) was used to 
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measure melting points. The one-dimensional 1H, and 13C, together with two-dimensional 
1H-13C hetero-correlation NMR experiments, were performed in DMSO-d6 utilizing Varian 
Inova 500 NMR spectrometer (Agilent Inc. PaloAlto, CA, USA) at 298 K. The 1H and 13C 
chemical shifts were reported relative to the SiMe4 (TMS) internal reference. The 
resonance assignments were achieved based on peak multiplicity and peak integration of 
recorded 1H data, supplemented with 13C and 1H-13C hetero-correlation spectra. Multiplets 
were assigned as s (singlet), d (doublet), t (triplet), dd (doublet of doublet), ddd (doublet of 
doublet of doublet) and m (multiplet). An LTQ Orbitrap Velos instrument (Thermo 
Scientific, Waltham, MA, USA) located at the Mass Spectrometry Laboratory of the 
Institute of Biochemistry and Biophysics PAS (Warsaw, Poland) was used to record high 
resolution mass spectra. A 6200 FT/IR spectrometer (Jasco, Easton, MD, USA) at the 
Laboratory of Optical Spectroscopy (Institute of Organic Chemistry PAS, Warsaw, 
Poland) was used to record IR spectra. 
3.1.2. Synthetic Procedures and Analytical Data 
The synthesis of tert-butyl (R)-(11a) and (S)-3-((4-methyl-3,6-dioxopiperazin-2-
yl)methyl)-1H-indole-1-carboxylate (11b) 
The 3.5 g of Fmoc-D-Trp(Boc)-OH (8a) or Fmoc-L-Trp(Boc)-OH (8b) (6.65 mmol, 1 
equiv.) was dissolved in 100 mL of methylene chloride and 2.57 g of Sar(OBzl)*TsOH (7.31 
mmol, 1.1 equiv., 9) followed by 3.41 g of PyBrop (7.31 mmol, 1.1 equiv.) and 2.33 mL of 
DIPEA (13.29 mmol, 2.0 equiv.) were added. The reaction mixture was stirred at room 
temperature for 18 h, and the progress of reaction was monitored by mass spectrometry. 
Then, the solvent was evaporated and crude products 10a and 10b were dissolved in 100 
mL of 25% piperidine in DMF. The reaction mixture was stirred at room temperature for 
18 h. Then, when the volatiles were evaporated under the reduced pressure, the residue 
was dissolved in acetone and finally evaporated with silica gel. The product was purified 
by column chromatography using ethyl acetate (removal of less polar by-products) 
followed by ethyl acetate:acetone 7:3 (isolation of main product). Yield: 1.13 g of 11a and 
1.15 g of 11b (48%). M.p.: 185.5–186.5 °C 1H NMR (CDCl3, 500 MHz) for 11a: 8.14 (d, 1H, J 
= 8.0 Hz, HAr); 7.56–7.52 (m, 1H, HAr); 7.49 (s, 1H, HAr); 7.36–7.30 (m, 1H, HAr); 7.28–7.21 
(m, 1H, HAr); 6.41 (s, 1H, NH), 4.34–4.27 (m, 1H, CH); 3.71 (dd, 1H, J = 1.0, J’ = 18.0 Hz, 
CH2); 3.44 (dd, 1H, J = 1.0, J’ = 18.0 Hz, CH2); 3.39 (ddd, 1H, J = 1.0, J’ = 3.5, J’’ = 14.5 Hz, 
CH2); 3.19–3.12 (m, 1H, CH2); 2.84 (s, 3H, Me), 1.67 (s, 9H, t-Bu). 13C NMR (CDCl3,125 MHz) 
for 11a: 165.7, 165.4, 149.5, 135.6, 129.7, 125.4, 125.0, 122.9, 119.2, 115.5, 114.2, 84.2, 55.1, 
51.5, 33.9, 30.7, 28.3; HRMS (ESI) 11a: m/z [2M + H]+ calculated for C38H47N6O8: 715.34499, 
found: 715.34570; IR (KBr) 11a: cm−1 3477, 3265, 2981, 2936, 1737, 1654, 1565, 1457, 1377, 
1339, 1319, 1271, 1228, 1201, 1158, 1106, 1081, 1025; 
The synthesis of tert-butyl (R)-(12a) and (S)-3-((1-(benzo[d][1,3]dioxol-5-ylmethyl)-4-
methyl-3,6-dioxopiperazin-2-yl)methyl)-1H-indole-1-carboxylate (12b) 
The 396 mg of tert-butyl (R)-3-((4-methyl-3,6-dioxopiperazin-2-yl)methyl)-1H-
indole-1-carboxylate (11a) or tert-butyl (S)-3-((4-methyl-3,6-dioxopiperazin-2-yl)methyl)-
1H-indole-1-carboxylate (11b) (1.11 mmol, 1 equiv.) were dissolved in 15 mL of DMF. 
After dissolution of 11a-b, 722 mg (2.22 mmol, 2 equiv.) of Cs2CO3, followed by 250 mg 
(1.16 mmol, 1.05 equiv.) of 5-(bromomethyl)benzo[d][1,3]dioxole were added and reaction 
mixture was stirred at room temperature for 18 h. The next day, the obtained solution was 
diluted with 100 mL of ethyl acetate, washed with water (3 × 100 mL), dried over 
magnesium sulfate and finally evaporated with silica gel. The product was purified by 
column chromatography using hexane: ethyl acetate 1:1. Yield: 461 mg (84%) for 12a and 
369 mg (68%) for 12b. M.p.: 195.0–196.0 °C 1H NMR (CDCl3, 500 MHz) for 12a: 8.12 (d, 1H, 
J = 8.0 Hz, HAr); 7.48–7.43 (m, 1H, HAr); 7.34–7.28 (m, 2H, HAr); 7.26–7.22 (m, 1H, HAr); 6.78–
6.71 (m, 3H, HAr); 5.96 (dd, 2H, J = 1.5, J’ = 4.0 Hz, CH2); 5.29 (d, 1H, J = 14.5 Hz, CH2); 4.02 
(t, 1H, J = 4.0 Hz, CH); 3.92 (d, 1H, J = 14.5 Hz, CH2); 3.43–3.35 (m, 2H, CH2); 3.17 (dd, 1H, 
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J = 5.0, J’ = 15.0 Hz, CH2); 2.69 (d, 1H, J = 17.0 Hz, CH2); 2.56 (s, 3H, Me), 1.68(s, 9H, t-Bu). 
13C NMR (CDCl3,125 MHz) for 12a: 166.5, 164.2, 149.5, 148.4, 147.8, 135.5, 129.8, 129.2, 
125.6, 125.1, 122.9, 122.4, 119.4, 115.4, 113.8, 109.1, 108.6, 101.4, 84.3, 59.1, 51.4, 47.0, 33.5, 
28.3, 27.3; HRMS (ESI) 12a: m/z [M+ calculated for C27H30N3O6: 492.21291, found: 492.21292; 
IR (KBr) 12a: cm−1 2978, 2927, 2898, 1742, 1658, 1494, 1472, 1450, 1373, 1324, 1296, 1252, 
1156, 1098, 1079, 1038; 
The synthesis of tert-butyl (R)-(13a) and (S)-3-((1-((6-bromobenzo[d][1,3]dioxol-5-
yl)methyl)-4-methyl-3,6-dioxopiperazin-2-yl) methyl)-1H-indole-1-carboxylate (13b); 
The 354 mg of tert-butyl (R)-3-((4-methyl-3,6-dioxopiperazin-2-yl)methyl)-1H-
indole-1-carboxylate (11a) or tert-butyl (S)-3-((4-methyl-3,6-dioxopiperazin-2-yl)methyl)-
1H-indole-1-carboxylate (11b) (0.99 mmol, 1 equiv.) was dissolved in 15 mL of DMF. After 
dissolution of 11a,b, 646 mg (1.98 mmol, 2 equiv.) of Cs2CO3, followed by 306 mg of 5-
bromo-6-(bromomethyl)benzo[d][1,3]dioxole (1.04 mmol, 1.05 equiv.) were added and 
reaction mixture was stirred at room temperature for 18 h. The next day, the obtained 
solution was diluted with 100 mL of ethyl acetate, washed with water (3 × 100 mL), dried 
over magnesium sulfate and finally evaporated with silica gel. The product was purified 
by column chromatography using hexane: ethyl acetate 1:1. Yield: 418 mg (74%) for 13a 
and 525 mg (93%) for 13b. M.p.: 94.5–95.5 °C 1H NMR (CDCl3, 500 MHz) for 13a: 8.12 (d, 
1H, J=8.0 Hz, HAr); 7.50–7.43 (m, 1H, HAr); 7.37–7.28 (m, 2H, HAr); 7.26–7.22 (m, 1H, HAr); 
7.01 (s, 1H, HAr); 6.84 (s, 1H, HAr); 5.99 (dd, 2H, J = 1.5 Hz, J’ = 5.5 Hz, CH2); 5.32 (d, 1H, J = 
15.0 Hz, CH2); 4.28 (d, 1H, J = 15.0 Hz, CH2); 4.21 (dd, 1H, J = 3.5 Hz, J’ = 4.5 Hz, CH); 3.44 
(ddd, 1H, J = 1.0 Hz, J’ = 4.5 Hz, J’’ = 15.0 Hz CH2); 3.37 (d, 1H, J = 17.5 Hz, CH2); 3.29 (dd, 
1H, J = 4.5 Hz, J’=15.0 Hz CH2); 2.62 (d, 1H, J = 17.5 Hz, CH2); 2.55 (s, 3H, Me); 1.68 (s, 9H, 
t-Bu); 13C NMR (CDCl3,125 MHz) for 13a: 166.5, 164.5, 149.5, 148.6, 148.2, 135.4, 129.8, 
128.0, 125.7, 125.0, 122.9, 119.4, 115.4, 114.9, 113.7, 112.8, 110.1, 102.2, 84.3, 59.3, 51.3, 46.2, 
33.5, 28.3, 27.4; HRMS (ESI) 13a: m/z [M + H]+ calculated for C27H29BrN3O6: 570.12342, 
572.12138, found: 570.12365, 572.12133; IR (KBr) for 13a: cm−1 3457, 3314, 3111, 3050, 2977, 
2928, 2076, 1734, 1667, 1567, 1504, 1479, 1454, 1407, 1371, 1330, 1256, 1232, 1197, 1156, 1113, 
1083, 1035; 
The synthesis of (R)-(6a) and (S)-3-((1H-indol-3-yl)methyl)-4-(benzo[d][1,3]dioxol-5-
ylmethyl)-1-methylpiperazine-2,5-dione (6b) 
Moreover, 277 mg of Boc-protected intermediate 12a and 321 mg of Boc-protected 
intermediate 12b were dissolved in TFA:dichloromethane mixture (1:4 v/v, 20 mL) and 
stirred at room temperature for 18 h. The next day, reaction mixtures were diluted with 
toluene (200 mL), evaporated under the reduced pressure and co-evaporated with toluene 
(two times, 50 mL). The residues were dissolved in 30 mL of THF and finally evaporated 
with silica gel. The products were purified by column chromatography using hexane: 
ethyl acetate 1:3. Yields: 190 mg (86%) for 6a and 192 mg (75%) for 6b. M.p.: 195.5–196.5 
°C 1H NMR (CDCl3, 500 MHz) for 6a: 8.63 (s, 1H, NH); 7.54–7.49 (m, 1H, HAr); 7.36–7.31 
(m, 1H, HAr); 7.21–7.14 (m, 1H, HAr); 7.14–7.08 (m, 1H, HAr); 6.87 (d, 1H, J = 2.5 Hz, HAr); 
6.82–6.77 (m, 1H, HAr); 6.77–6.74 (m, 2H, HAr); 5.97–5.94 (m, 2H, CH2); 5.35 (d, 1H, J = 14.5 
Hz, CH2); 4.18 (dd, 1H, J = 3.0 Hz, J’ = 4.5 Hz, CH); 3.92 (d, 1H, J = 14.5 Hz, CH2); 3.51 (dd, 
1H, J = 3.0 Hz, J’ = 15.0 Hz, CH2); 3.29–3.17 (m, 2H, CH2); 2.44 (s, 3H, Me); 2.15 (d, 1H, J = 
17.0 Hz, CH2); 13C NMR (CDCl3,125 MHz) for 6a: 166.8, 165.0, 148.4, 147.7, 136.2, 129.2, 
127.1, 124.4, 122.6, 122.3, 120.0, 119.2, 111.3, 109.0, 108.6, 108.5, 101.4, 59.5, 51.1, 46.7, 33.3, 
27.20. HRMS (ESI) 6a: m/z [M + H]+ calculated for C22H22N3O4: 392.16048, found: 392.16047; 
IR (KBr) 6a: cm−1 3262, 3048, 2979, 2896, 1658, 1488, 1439, 1408, 1331, 1285, 1245, 1193, 1159, 
1130, 1100, 1033; 
The synthesis of (R)-(7a) and (S)-3-((1H-indol-3-yl)methyl)-4-((6-
bromobenzo[d][1,3]dioxol-5-yl)methyl)-1-methyl-piperazine-2,5-dione (7b); 
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Overall, 338 mg of Boc-protected intermediate 13a and 364 mg of Boc-protected 
intermediate 13b were dissolved in TFA:dichloromethane mixture (1:4 v/v, 20 mL) and 
stirred at room temperature for 18 h. The next day, reaction mixtures were diluted with 
toluene (200 mL), evaporated under the reduced pressure and co-evaporated with toluene 
(two times, 50 mL). The residues were dissolved in 30 mL of THF and finally evaporated 
with silica gel. The products were purified by column chromatography using hexane: 
ethyl acetate 1:3. Yields: 265 mg (95%) for 7a and 249 mg (83%) for 7b. M.p.: 104.5–105.5 
°C 1H NMR (CDCl3, 500 MHz) for 7a: 8.44 (s, 1H, NH); 7.55–7.50 (m, 1H, HAr); 7.38–7.33 
(m, 1H, HAr); 7.22–7.15 (m, 1H, HAr); 7.15–7.10 (m, 1H, HAr); 7.02 (s, 1H, H, HAr); 6.93 (d, 
1H, J = 2.5 Hz, HAr); 6.83 (s, 1H, HAr); 5.98 (dd, 2H, J = 1.5 Hz, J’ = 4.5 Hz, CH2); 5.37 (d, 1H, 
J = 15.0 Hz, CH2); 4.26 (d, 1H, J = 15.0 Hz, CH2); 4.18 (dd, 1H, J = 2.5 Hz, J’ = 4.5 Hz, CH); 
3.56 (dd, 1H, J = 2.5 Hz, J’ = 15.0 Hz, CH2); 3.32 (dd, 1H, J = 4.5 Hz, J’ = 15.0 Hz, CH2); 3.23 
(d, 1H, J = 17.0 Hz, CH2); 2.44 (s, 3H, Me); 2.12 (d, 1H, J = 17.0 Hz, CH2); 13C NMR 
(CDCl3,125 MHz) for 7a: 166.8, 165.2, 148.5, 148.1, 136.2, 127.9, 127.1, 124.5, 122.7, 120.0, 
119.3, 114.9, 112.9, 111.3, 110.0, 108.7, 102.2, 59.7, 51.1, 46.1, 33.4, 27.5; HRMS (ESI) for 7a: 
m/z [M + H]+ calculated for C22H21BrN3O4: 470.07100, 472.06895, found: 470.07113, 
470.06903; IR (KBr) for 8a: cm−1 3281, 3052, 2921, 1658, 1477, 1329, 1235, 1196, 1159, 1110, 
1035; 
3.1.3. Crystallographic Studies 
Good quality single crystals of 11a, 12a, 6a and 1 (tadalafil) were selected for the X-
ray diffraction experiments at T = 100(2) K. Diffraction data were collected on the Agilent 
Technologies SuperNova Dual Source diffractometer with CuKα radiation (λ = 1.54184 Å) 
using CrysAlis RED software [CrysAlis CCD and CrysAlis RED, Oxford Diffraction, Oxford 
Diffraction Ltd.: Yarnton, UK, 2008]. The multi-scan empirical absorption correction using 
spherical harmonics (11a, 12a and 1) and analytical numeric absorption correction using 
a multifaceted crystal model based on expressions derived by R.C. Clark and J.S. Reid (6a) 
[54], implemented in SCALE3 ABSPACK scaling algorithm, was applied (CrysAlis CCD 
and CrysAlis RED, Oxford Diffraction, Oxford Diffraction Ltd.: Yarnton, 2008). The 
structural determination procedure was carried out using the SHELX package [55]. The 
structures were solved with direct methods and then successive least-square refinement 
was carried out based on the full-matrix least-squares method on F2 using the SHELXL 
program [55]. All H-atoms linked to the N-atoms were located on a Fourier difference 
map and refined with Uiso(H) = 1.2Ueq(N). In case of 11a, the N−H bond lengths were 
restrained to a distance of 0.87 Å. Other H-atoms were positioned geometrically, with C–
H equal to 0.93, 0.96, 0.97 and 0.98 Å for the aromatic, methyl, methylene and methine H-
atoms, respectively, and constrained to ride on their parent atoms with Uiso(H) = xUeq(C), 
where x = 1.2 for the aromatic, methylene and methine, and 1.5 for the methyl-H-atoms, 
respectively. All presented molecular interactions were found using the PLATON 
program [56]. The figures for this publication were prepared using Olex2 and Mercury 
programs [57,58]. 
3.2. Biology 
3.2.1. Cell Culture 
The following human cell lines were used in this study: (i) epidermoid carcinoma A-
431 (ATCC® CRL-1555), (ii) lung carcinoma A549 (ATCC® CCL-185), (iii) colorectal 
carcinoma HCT116 (ATCC® CCL-247), (iv) HCT116p53−/−, (v) glioblastoma U-87 MG 
(ATCC® HTB-14), (vi) glioblastoma U-251 MG (ECACC 09063001), (vii) breast 
adenocarcinoma MCF7 (ATCC® HTB-22), (viii) breast adenocarcinoma MDA-MB-231 
(ECACC 92020424), (ix) papillomavirus-related cervical squamous cell carcinoma SKG-
IIIa (RRID:CVCL_1704), (x) cervical adenocarcinoma HeLa (ATCC® CCL-2), (xi) bone 
osteosarcoma U-2 OS (ATCC® HTB-96), (xii) hepatocellular carcinoma HEPG2 (ATCC® 
HB-8065), (xiii) larynx squamous cell carcinoma BICR 18 (ECACC 06051601), (ix) kidney 
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HEK 293T (ATCC® CRL-11268), (xv) normal lung fibroblasts MRC-5 (ATCC® CCL-171), 
(xvi) normal fibroblasts BJ (ATCC® CRL-2522). The HCT116p53−/− cell line was a kind gift 
from professor Bert Vogelstein (John Hopkin’s University, Baltimore, MD, USA). The 
remaining cell lines were purchased from ATCC (Manassas, VA, USA) or Sigma-Aldrich 
by Merck (Darmstadt, Germany). 
Cells were cultured in minimal or Dulbecco’s modified Eagle’s or Ham’s F10 medium 
supplemented with 10% fetal bovine serum (Gibco by Thermo Fisher Scientific, Waltham, 
MA, USA) and (for BICR 18) 0.4 μg/mL hydrocortizone (Sigma-Aldrich by Merck, 
Darmstadt, Germany) under standard culture conditions (37 °C, 5% CO2) in a humidified 
incubator with an atmospheric oxygen. 
3.2.2. Cell Viability Assay 
The viability of cells was assayed by measuring the conversion of MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) to the formazan (the rate of this 
reaction is proportional to the number of surviving cells). Cells were seeded in a 96-well 
plate at a density of 2500–3500 cells per well, 24 h before treatment. Treatment with 
compounds 6a,b, 7a,b, tadalafil and cisplatin (2.5–160 μM) was performed for 72 h. MTT 
stock solution (Sigma-Aldrich) was added at the final concentration 0.5 mg/mL. After 4 h 
of incubation at 37 °C, water-insoluble formazan was dissolved in a lysis buffer containing 
20% SDS, 50% DMF, 2.5% hydrochloric acid and 2.5% acetic acid. Optical densities were 
measured at 570 nm using a scanning multi-well spectrophotometer (PARADIGM 
Detection Platform; Beckman Coulter, Brea, CA, USA). At least three independent 
experiments of viability were conducted. 
3.2.3. Enzyme Inhibition 
The inhibitory effect of the tested compounds was measured using colorimetric PDE 
Activity Assay Kit (Abcam, Cambridge, UK). This assay allows the quantification of 5′-
nucleotide released in the reaction catalyzed by tested phosphodiesterase, PDE5, using 
the additional enzyme 5′-nucleotidase to cleave the mentioned product, and next, using 
modified Malachite Green assay, the phosphate is quantified. The assay was carried in a 
96-well plate at a volume of 40 μL in an assay buffer, containing 40 ng recombinant human 
PDE5A/PDE5 protein (Abcam), 200 μM cGMP, 25 kU 5′-nucleotidase and serially diluted 
ligand to preserve 4% of DMSO. The reaction was initiated with the enzyme and kept 
going for 20 min at 37 °C. The reaction was stopped by adding 80 μL of Green Assay 
reagent. After incubation at room temperature for 30 min (to develop color proportional 
to phosphate content), the absorbance at 620 nm was measured with The SpectraMax iD3 
Multi-Mode Microplate Reader (Molecular Devices, San Jose, CA, USA). Inhibitors 
concentrations varied in the range of 2 pM–200 μM. Each experiment was repeated 4–5 
times and IC50 values were calculated by global fitting of the sigmoidal dose response 
equation implemented in Origin 9.0 package (www.originlab.com). For each experiment, 
control reaction with no enzyme added and without inhibitor was also performed. 
3.2.4. Platelet Aggregation in Platelet Rich Plasma 
Multiplate test cells for turbidimetric aggregometry and collagen were purchased 
from Chronolog Co (Havertown, PA, USA). Diethylammonium (Z)-1-(N,N-
diethylamino)diazen-1-ium-1,2-diolate (DEA-NO) was purchased from Sigma-Aldrich by 
Merck. The blood samples were centrifuged for 12 min at 190× g to obtain platelet-rich 
plasma (PRP). The platelet count in the PRP was adjusted to 2 × 108 platelets/mL prior to 
its use in experiments. Five minutes prior to measurements, samples were added with a 
tested compound (dissolved in 0.1% DMSO), control samples were added with 0.1% 
DMSO. DEA-NO was added to the final concentration of 500 nM, and shortly after, 
collagen was added to each sample to a final concentration of 2 μg/mL to induce platelet 
aggregation, which was thereafter monitored for 10 min using an optical aggregometer 
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Chrono-Log 490-2D (Chrono-Log, Havertown, PA, USA). The total area under the 
aggregation curve (AUC) and the maximal value of platelet aggregation (Amax,U) was 
recorded. 
3.2.5. Patients and Blood Collection 
Blood was drawn from healthy donors. The samples were collected into a vacuum 
tube containing 0.105 M buffered sodium citrate, for optical aggregation. The study was 
performed under the guidelines of the Helsinki Declaration for human research and 
approved by the Medical University of Lodz committee on the Ethics of Research in 
Human Experimentation (approval numer: RNN/43/17/KE). 
3.2.6. Caenorhabditis Elegans 
Worms were maintained and handled in standard conditions, as described by 
Brenner [59]. Worms were cultured at 20 °C on plates seeded with E. coli HB101. Wild type 
C. elegans N2 strain was used in this study. For the toxicological test, worms were cultured 
in liquid S-medium in 96 well plates. Each well contained 100 μL medium and was seeded 
with heat inactivated HB101 bacteria. 50 L4 worms were transferred to each well. The 
viability of worms was assessed after 24 and 48 h by visual inspection; thrashing worms 
were scored alive and straight, non-moving as dead. 
4. Conclusions 
In the present study, we synthesized four novel analogues of PDE5 inhibitor—
tadalafil, and compared their physicochemical and biological properties with the parent 
compound. The obtained crystal structures, due to ligands flexibility, revealed significant 
structural differences and interaction schemes in the solid state. In the cytotoxic assays, in 
the most cases, newly synthesized compounds exhibited a weaker effect than tadalafil, 
except for bromine-substituted compounds 7a and 7b, which showed a stronger cytotoxic 
effect then the parent compound on HEK 293T and MC F7 cell lines. The effect on MCF7 
is especially interesting, as IC50 = 55.29 μM observed for tadalafil dropped to the 28.9 μM 
in case of (R)-3-((1H-indol-3-yl)methyl)-4-((6-bromobenzo[d][1,3]dioxol-5-yl)methyl)-1-
methylpiperazine-2,5-dione (7a) and 36.32 μM for (S)-3-((1H-indol-3-yl)methyl)-4-((6-
bromobenzo[d][1,3]dioxol-5-yl)methyl)-1-methylpiperazine-2,5-dione (7b). As the newly 
prepared compounds, in two different independent assays, turned out to be significantly 
weaker PDE5 inhibitors, we concluded that structural changes introduced to the tadalafil 
structure diminished their interactions with enzyme, and the rigidity of molecules is a key 
factor responsible for its biological activity. Consequently, the enhanced cytotoxic effect 
observed in the breast cancer cell line MCF7, worthy of further biological research, is not 
in this case related to the inhibition of PDE5 activity, but results from another, yet 
undiscovered mechanism of action. The synthesized products are low molecular weight 
compounds with lead-like properties suitable for a further medicinal chemistry 
optimization program. Further research on the improvement of the cytotoxic effect and 
the selectivity of the tested compounds, especially to the MCF7 breast cancer cell line, is 
being conducted in our laboratory and will be published in due course. 
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